

---

# CDISC SDTM & Standard Reporting

*One System*

# Authors/Contributors

---

- Merck & Co., Inc.
  - Ram Radhakrishnan, Manager, Statistical Information Systems
  - Thomas W. Dobbins, Ph.D., Executive Director, Biostatistics and Statistical Information Systems
  - Paul DeLucca, Ph.D., Associate Director, Biostatistics and Statistical Information Systems
  - Susan Neidlinger, Manager, Statistical Computing

# Authors/Contributors

---

- Nth Analytics

- Michael Todd, President
- Anne Russotto, Project Manager
- T. Richard Garrity, Software Architect

# Merck Background

---

- Biostatistics and Statistical Information Systems (BASIS)
  - Statistics Organization in Clinical Development Programs
  - Provides statistical and programming support for the design, analysis, and reporting of clinical trials data for approved drugs
  - Results used in publications and promotions
    - Some support for Registration (sNDAs)


# Legacy Process

---


- Data in disparate databases and structures
- Multiple versions/sets of programs to generate Tables and Listings (T&Ls)
- Distinct processes for Analysis & Reporting (A&R)

# Legacy Process

Project 1



Project 2



... etc.

# Legacy Process (continued)

---

- Challenges:
  - Combining and reporting data across studies
  - Inefficient Process:
    - Resource burden of maintaining multiple reporting tools, programs, validation, etc.
    - Sub-optimal process for response to requests for additional Strategic Analyses
      - e.g. sub group analyses with classifications and covariates

# BASIS A&R Vision

---

- “One-step away from knowledge” statistical analysis and reporting process



# BASIS A&R Strategic Goal

---

- A common (SAS-based) platform
- A Structured Data Model
- Access to all clinical trial data independent of time, place, database, or compound
- One-step away access to data for statistical analysis and reporting to any level of complexity

# Vision & Strategic Goal Implementation

---

- Unified A&R Environment
- Standard SAS Dataset Model
  - Independent of Data Source/System
  - Define a structured analysis data model
  - Metadata-driven
    - All derivations at dataset level
  - Standardized by Therapeutic Area
    - but allows for customization
  - Standard Code and Template Library to generate datasets, T&Ls

# New A&R Process Advantages

---

- Easy to combine data across studies
- Unified (integrated) A&R process
- Reusable, standard code for datasets and T&Ls
- Easy to maintain, validate, and update

# New A&R Process Advantages

---

- Optimal process for addressing additional requests for strategic analyses
- Proactively anticipate and plan for additional requests
- Easily respond to unanticipated requests

# Nth Analytics Solution

---

- Part I - An ETL Process to generate CDISC SDTM+ datasets
- Part II – A Generic Table System to generate standard Merck reports from the SDTM+ datasets

# Nth Analytics Solution

---

- ETL procedure to create CDISC SDTM datasets
  - Maps source data into SDTM domains
  - Provides an automated method for specifying data sources and algorithms
  - Provides all information required for the FDA-mandated "DEFINE.PDF"

# Why Choose SDTM?

---

- SDTM adoption approaching critical mass
- Standard data structure simplifies reporting
- Merck is adopting CDISC standards
- Issues:
  - SDTM structures exclude derived variables
  - ADaM not finalized
  - Need to include all variables collected

# What About ADaM?

---

- ADaM is an evolving standard
  - not finalized in Aug 2004
  - adoption would have been premature
- Some ADaM principles were applied:
  - Build on SDTM structures
  - One PROC away
  - SAS dates, not ISO dates
  - Numeric codes for sorting



# Special Considerations

---

- In determining a solution, there were some special considerations:
  - Studies not intended for submission
  - Full CDISC compliance not critical
    - Unless studies are included in a submission
  - Focused reporting objectives


# Possible Implementation Strategies

---

- Parallel method
  - develop SDTM and analysis data simultaneously
- Retrospective method
  - develop analysis data first, then derive SDTM from the analysis data
- Linear method
  - develop SDTM first, then create analysis data from SDTM

# Hybrid Method

---



# Hybrid Method - Advantages

---

- Analysis file programs are useful to reviewer and as documentation
- Encourages standardization of analysis datasets
- Variables or records in SDTM that need statistical input can be obtained from analysis files
- Derived records or supplemental variables can be easily added to SDTM if needed or desired
  - Disposition events
  - Population flags

## Possible Implementation Strategies (cont.)

---

- Hybrid method
  - “SDTM+ conforms to standards but may not be complete with respect to variables or records that need clinical or statistical input or other permitted variables”
  - “May contain non-SDTM variables needed for analysis”

# SDTM+ to SDTM Final – Submission Ready

---

- Changes related to submission:
  - Drop non-SDTM variables
    - automated process because these variables are flagged in metadata
  - Create trial design datasets
  - Create RELREC, SC, SUPPQUAL
  - Create ISO dates/times
    - SAS formats make this easy to automate

## Preparing for Submission

---

- The SDTM+ datasets are the source for ADaM datasets
- Easily convert SDTM+ to submission-ready SDTM datasets
- Documentation = mapping table
- Standalone submission-ready programs built-in


# Nth Analytics Solution - Reporting

---

- STD<sup>M</sup>+ simplifies reporting
- Generic Table System
  - Calling programs use SAS Macros to generate standard reports from SD<sup>T</sup><sup>M</sup>+
  - Achieves standardization, and is easy for programmers to use



# Implementation Methodology



# Nth Analytics Solution

---

- Why this approach worked for Merck
  - Did not disrupt existing clinical trial systems
  - It can be applied to legacy data
  - Minimal rework
    - only metadata will change for each study

# Nth Analytics Solution

---

- Why this approach worked for Merck (cont.)
  - Table driven metadata provides automatic documentation
  - Effort to produce subsequent SDTM files is minimized
    - only study-specific situations require additional coding

# Merck - Implementation

---

- Tool has been installed and used for 8 studies in 3 Therapeutic Areas
  - Multiple eDC versions with different structures
- Currently being used in 5 ongoing studies
  - 2 CRO studies
  - 2 eDC systems

# Adoption with New Studies

---

- Minor customization for new studies
  - Mapping table process
  - Macros
  - Preprocessing code allows for further customization

# Merck - Benefits

---

- Increased efficiency by over 50%
  - Reduced programming time, resources
  - Limited validation effort
    - standards
    - single reporting system
- All T&Ls delivered within 5-10 days from DB lock

## Merck Benefits - (continued)

---

- Consistency in A&R ground rules
- Standard data exchange protocol
  - transparent and portable
- Timely response for Strategic Analyses and *ad hoc* requests